Z-160

DB12743InvestigationalSmall molecule

Z160 has been used in trials studying the treatment of Postherpetic Neuralgia and Lumbosacral Radiculopathy.

Mechanism: Pharmacologically active on Voltage-dependent N-type calcium channel subunit alpha-1B
Curator reviewed
Formula / weight: C₃₂H₃₂N₂O · 460.621 g/mol (avg)
Also known as: 1-(4-Benzhydryl-piperazin-1-yl)-3,3-diphenylpropan-1-one · 1-(4-Benzhydrylpiperazin-1-yl)-3,3-Diphenylpropan-1-one
Code names: Z-160

Resolves to

Compound

Structure

InChIKeyVCPMZDWBEWTGNW-UHFFFAOYSA-NSMILESO=C(CC(C1=CC=CC=C1)C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Z-160, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.